Selected research
Industry Research
Alpha-1 Lung Disease Industry Research Report 2026
Market perspective
The global Alpha-1 Lung Disease market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Alpha-1 Lung Disease market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Alpha-1 Lung Disease market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Alpha-1 Lung Disease market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Alpha-1 Lung Disease include Takeda, Pfizer, GlaxoSmithKline, Baxter, AstraZeneca, Vertex Pharmaceuticals, Teva Pharmaceutical Industries, ProMetic Life Sciences and ProBioGen, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Alpha-1 Lung Disease market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Alpha-1 Lung Disease.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Alpha-1 Lung Disease Market by Company
Takeda
Pfizer
GlaxoSmithKline
Baxter
AstraZeneca
Vertex Pharmaceuticals
Teva Pharmaceutical Industries
ProMetic Life Sciences
ProBioGen
LFB Biomedicaments
Kedrion Group
Kamada Ltd
Grifols
CSL Behring
Chiesi Pharmaceuticals
Boehringer Ingelheim
Biogen
Baxalta
Arrowhead Research Corporation
Abeona Therapeutics
Alpha-1 Lung Disease Segment by Type
Non-CF Bronchiectasis(NCFB)
Cystic Fibrosis(CF)
Augmentation Therapy
Other
Alpha-1 Lung Disease Segment by Application
Pharmacies
Hospitals
Specialty Clinics
Others
Alpha-1 Lung Disease Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Alpha-1 Lung Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Alpha-1 Lung Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Alpha-1 Lung Disease.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Alpha-1 Lung Disease companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Non-CF Bronchiectasis(NCFB)
- Cystic Fibrosis(CF)
- Augmentation Therapy
- Other
Applications
- Pharmacies
- Hospitals
- Specialty Clinics
- Others
Companies covered
- Takeda
- Pfizer
- GlaxoSmithKline
- Baxter
- AstraZeneca
- Vertex Pharmaceuticals
- Teva Pharmaceutical Industries
- ProMetic Life Sciences
- ProBioGen
- LFB Biomedicaments
- Kedrion Group
- Kamada Ltd
- Grifols
- CSL Behring
- Chiesi Pharmaceuticals
- Boehringer Ingelheim
- Biogen
- Baxalta
- Arrowhead Research Corporation
- Abeona Therapeutics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Alpha-1 Lung Disease by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Non-CF Bronchiectasis(NCFB)
- 2.2.3 Cystic Fibrosis(CF)
- 2.2.4 Augmentation Therapy
- 2.2.5 Other
- 2.3 Alpha-1 Lung Disease by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Pharmacies
- 2.3.3 Hospitals
- 2.3.4 Specialty Clinics
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Alpha-1 Lung Disease Breakdown Data by Type
- 3.1 Global Alpha-1 Lung Disease Historic Market Size by Type (2021-2026)
- 3.2 Global Alpha-1 Lung Disease Forecasted Market Size by Type (2027-2032)
4 Alpha-1 Lung Disease Breakdown Data by Application
- 4.1 Global Alpha-1 Lung Disease Historic Market Size by Application (2021-2026)
- 4.2 Global Alpha-1 Lung Disease Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Alpha-1 Lung Disease Market Perspective (2021-2032)
- 5.2 Global Alpha-1 Lung Disease Growth Trends by Region
- 5.2.1 Global Alpha-1 Lung Disease Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Alpha-1 Lung Disease Historic Market Size by Region (2021-2026)
- 5.2.3 Alpha-1 Lung Disease Forecasted Market Size by Region (2027-2032)
- 5.3 Alpha-1 Lung Disease Market Dynamics
- 5.3.1 Alpha-1 Lung Disease Industry Trends
- 5.3.2 Alpha-1 Lung Disease Market Drivers
- 5.3.3 Alpha-1 Lung Disease Market Challenges
- 5.3.4 Alpha-1 Lung Disease Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Alpha-1 Lung Disease Players by Revenue
- 6.1.1 Global Top Alpha-1 Lung Disease Players by Revenue (2021-2026)
- 6.1.2 Global Alpha-1 Lung Disease Revenue Market Share by Players (2021-2026)
- 6.2 Global Alpha-1 Lung Disease Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Alpha-1 Lung Disease Head Office and Area Served
- 6.4 Global Alpha-1 Lung Disease Players, Product Type & Application
- 6.5 Global Alpha-1 Lung Disease Manufacturers Established Date
- 6.6 Global Alpha-1 Lung Disease Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Alpha-1 Lung Disease Market Size (2021-2032)
- 7.2 North America Alpha-1 Lung Disease Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Alpha-1 Lung Disease Market Size by Country (2021-2026)
- 7.4 North America Alpha-1 Lung Disease Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Alpha-1 Lung Disease Market Size (2021-2032)
- 8.2 Europe Alpha-1 Lung Disease Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Alpha-1 Lung Disease Market Size by Country (2021-2026)
- 8.4 Europe Alpha-1 Lung Disease Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Alpha-1 Lung Disease Market Size (2021-2032)
- 9.2 Asia-Pacific Alpha-1 Lung Disease Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Alpha-1 Lung Disease Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Alpha-1 Lung Disease Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Alpha-1 Lung Disease Market Size (2021-2032)
- 10.2 South America Alpha-1 Lung Disease Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Alpha-1 Lung Disease Market Size by Country (2021-2026)
- 10.4 South America Alpha-1 Lung Disease Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Alpha-1 Lung Disease Market Size (2021-2032)
- 11.2 Middle East & Africa Alpha-1 Lung Disease Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Alpha-1 Lung Disease Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Alpha-1 Lung Disease Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Takeda
- 12.1.1 Takeda Company Information
- 12.1.2 Takeda Business Overview
- 12.1.3 Takeda Revenue in Alpha-1 Lung Disease Business (2021-2026)
- 12.1.4 Takeda Alpha-1 Lung Disease Product Portfolio
- 12.1.5 Takeda Recent Developments
- 12.2 Pfizer
- 12.2.1 Pfizer Company Information
- 12.2.2 Pfizer Business Overview
- 12.2.3 Pfizer Revenue in Alpha-1 Lung Disease Business (2021-2026)
- 12.2.4 Pfizer Alpha-1 Lung Disease Product Portfolio
- 12.2.5 Pfizer Recent Developments
- 12.3 GlaxoSmithKline
- 12.3.1 GlaxoSmithKline Company Information
- 12.3.2 GlaxoSmithKline Business Overview
- 12.3.3 GlaxoSmithKline Revenue in Alpha-1 Lung Disease Business (2021-2026)
- 12.3.4 GlaxoSmithKline Alpha-1 Lung Disease Product Portfolio
- 12.3.5 GlaxoSmithKline Recent Developments
- 12.4 Baxter
- 12.4.1 Baxter Company Information
- 12.4.2 Baxter Business Overview
- 12.4.3 Baxter Revenue in Alpha-1 Lung Disease Business (2021-2026)
- 12.4.4 Baxter Alpha-1 Lung Disease Product Portfolio
- 12.4.5 Baxter Recent Developments
- 12.5 AstraZeneca
- 12.5.1 AstraZeneca Company Information
- 12.5.2 AstraZeneca Business Overview
- 12.5.3 AstraZeneca Revenue in Alpha-1 Lung Disease Business (2021-2026)
- 12.5.4 AstraZeneca Alpha-1 Lung Disease Product Portfolio
- 12.5.5 AstraZeneca Recent Developments
- 12.6 Vertex Pharmaceuticals
- 12.6.1 Vertex Pharmaceuticals Company Information
- 12.6.2 Vertex Pharmaceuticals Business Overview
- 12.6.3 Vertex Pharmaceuticals Revenue in Alpha-1 Lung Disease Business (2021-2026)
- 12.6.4 Vertex Pharmaceuticals Alpha-1 Lung Disease Product Portfolio
- 12.6.5 Vertex Pharmaceuticals Recent Developments
- 12.7 Teva Pharmaceutical Industries
- 12.7.1 Teva Pharmaceutical Industries Company Information
- 12.7.2 Teva Pharmaceutical Industries Business Overview
- 12.7.3 Teva Pharmaceutical Industries Revenue in Alpha-1 Lung Disease Business (2021-2026)
- 12.7.4 Teva Pharmaceutical Industries Alpha-1 Lung Disease Product Portfolio
- 12.7.5 Teva Pharmaceutical Industries Recent Developments
- 12.8 ProMetic Life Sciences
- 12.8.1 ProMetic Life Sciences Company Information
- 12.8.2 ProMetic Life Sciences Business Overview
- 12.8.3 ProMetic Life Sciences Revenue in Alpha-1 Lung Disease Business (2021-2026)
- 12.8.4 ProMetic Life Sciences Alpha-1 Lung Disease Product Portfolio
- 12.8.5 ProMetic Life Sciences Recent Developments
- 12.9 ProBioGen
- 12.9.1 ProBioGen Company Information
- 12.9.2 ProBioGen Business Overview
- 12.9.3 ProBioGen Revenue in Alpha-1 Lung Disease Business (2021-2026)
- 12.9.4 ProBioGen Alpha-1 Lung Disease Product Portfolio
- 12.9.5 ProBioGen Recent Developments
- 12.10 LFB Biomedicaments
- 12.10.1 LFB Biomedicaments Company Information
- 12.10.2 LFB Biomedicaments Business Overview
- 12.10.3 LFB Biomedicaments Revenue in Alpha-1 Lung Disease Business (2021-2026)
- 12.10.4 LFB Biomedicaments Alpha-1 Lung Disease Product Portfolio
- 12.10.5 LFB Biomedicaments Recent Developments
- 12.11 Kedrion Group
- 12.11.1 Kedrion Group Company Information
- 12.11.2 Kedrion Group Business Overview
- 12.11.3 Kedrion Group Revenue in Alpha-1 Lung Disease Business (2021-2026)
- 12.11.4 Kedrion Group Alpha-1 Lung Disease Product Portfolio
- 12.11.5 Kedrion Group Recent Developments
- 12.12 Kamada Ltd
- 12.12.1 Kamada Ltd Company Information
- 12.12.2 Kamada Ltd Business Overview
- 12.12.3 Kamada Ltd Revenue in Alpha-1 Lung Disease Business (2021-2026)
- 12.12.4 Kamada Ltd Alpha-1 Lung Disease Product Portfolio
- 12.12.5 Kamada Ltd Recent Developments
- 12.13 Grifols
- 12.13.1 Grifols Company Information
- 12.13.2 Grifols Business Overview
- 12.13.3 Grifols Revenue in Alpha-1 Lung Disease Business (2021-2026)
- 12.13.4 Grifols Alpha-1 Lung Disease Product Portfolio
- 12.13.5 Grifols Recent Developments
- 12.14 CSL Behring
- 12.14.1 CSL Behring Company Information
- 12.14.2 CSL Behring Business Overview
- 12.14.3 CSL Behring Revenue in Alpha-1 Lung Disease Business (2021-2026)
- 12.14.4 CSL Behring Alpha-1 Lung Disease Product Portfolio
- 12.14.5 CSL Behring Recent Developments
- 12.15 Chiesi Pharmaceuticals
- 12.15.1 Chiesi Pharmaceuticals Company Information
- 12.15.2 Chiesi Pharmaceuticals Business Overview
- 12.15.3 Chiesi Pharmaceuticals Revenue in Alpha-1 Lung Disease Business (2021-2026)
- 12.15.4 Chiesi Pharmaceuticals Alpha-1 Lung Disease Product Portfolio
- 12.15.5 Chiesi Pharmaceuticals Recent Developments
- 12.16 Boehringer Ingelheim
- 12.16.1 Boehringer Ingelheim Company Information
- 12.16.2 Boehringer Ingelheim Business Overview
- 12.16.3 Boehringer Ingelheim Revenue in Alpha-1 Lung Disease Business (2021-2026)
- 12.16.4 Boehringer Ingelheim Alpha-1 Lung Disease Product Portfolio
- 12.16.5 Boehringer Ingelheim Recent Developments
- 12.17 Biogen
- 12.17.1 Biogen Company Information
- 12.17.2 Biogen Business Overview
- 12.17.3 Biogen Revenue in Alpha-1 Lung Disease Business (2021-2026)
- 12.17.4 Biogen Alpha-1 Lung Disease Product Portfolio
- 12.17.5 Biogen Recent Developments
- 12.18 Baxalta
- 12.18.1 Baxalta Company Information
- 12.18.2 Baxalta Business Overview
- 12.18.3 Baxalta Revenue in Alpha-1 Lung Disease Business (2021-2026)
- 12.18.4 Baxalta Alpha-1 Lung Disease Product Portfolio
- 12.18.5 Baxalta Recent Developments
- 12.19 Arrowhead Research Corporation
- 12.19.1 Arrowhead Research Corporation Company Information
- 12.19.2 Arrowhead Research Corporation Business Overview
- 12.19.3 Arrowhead Research Corporation Revenue in Alpha-1 Lung Disease Business (2021-2026)
- 12.19.4 Arrowhead Research Corporation Alpha-1 Lung Disease Product Portfolio
- 12.19.5 Arrowhead Research Corporation Recent Developments
- 12.20 Abeona Therapeutics
- 12.20.1 Abeona Therapeutics Company Information
- 12.20.2 Abeona Therapeutics Business Overview
- 12.20.3 Abeona Therapeutics Revenue in Alpha-1 Lung Disease Business (2021-2026)
- 12.20.4 Abeona Therapeutics Alpha-1 Lung Disease Product Portfolio
- 12.20.5 Abeona Therapeutics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst